Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer

作者：Yufei Wang, Tianyi Fang, Yimin Wang, Xin Yin, Lei Zhang, Xinghai Zhang, Daoxu Zhang, Yao Zhang, Xibo Wang, Hao Wang, Yingwei Xue · 发表于：BMC Cancer · 年份：2022 · DOI：10.1186/s12885-022-09594-1 · 被引用次数：12 · 研究领域：Histone Deacetylase Inhibitors Research、Cholangiocarcinoma and Gallbladder Cancer Studies、Peptidase Inhibition and Analysis

BACKGROUND: The prognosis of Borrmann type III advanced gastric cancer (AGC) is known to vary significantly among patients. This study aimed to determine which differentially expressed genes (DEGs) are directly related to the survival time of Borrmann type III AGC patients and to construct a prognostic model. METHODS: We selected 25 patients with Borrmann type III AGC who underwent radical gastrectomy. According to the difference in overall survival (OS), the patients were divided into group A (OS<1 year, n=11) and group B (OS>3 years, n=14). DEGs related to survival time in patients with Borrmann type III AGC were determined by mRNA sequencing. The prognosis and functional differences of DEGs in different populations were determined by The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) public databases. The expression of mRNA and protein in cell lines was detected by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot (WB). Immunohistochemical (IHC) staining was used to detect protein expression in the paraffin-embedded tissues of 152 patients with Borrmann type III AGC who underwent radical gastrectomy. After survival analysis, nomograms were constructed to predict the prognosis of patients with Borrmann type III AGC. RESULTS: Arylacetamide deacetylase (AADAC) is a survival-related DEG in patients with Borrmann type III AGC. The higher the expression level of its mRNA and protein is, the better the prognosis of pat...